CompactCalc is an enhanced scientific calculator for Windows with an expression editor. It embodies prime numbers, rational numbers, generic floating-point routines, hyperbolic and transcendental routines. Its underling implementation encompasses the highest precision, sturdiness and multi-functionality. With the brilliant designs and powerful features of CompactCalc, you can bring spectacular results to your calculating routines.
ScienCalc is a convenient and powerful scientific calculator. ScienCalc calculates mathematical expression. It supports the common arithmetic operations (+, -, *, /) and parentheses.
The program contains high-performance arithmetic, trigonometric, hyperbolic and transcendental calculation routines. All the function routines therein map directly to Intel 80387 FPU floating-point machine instructions.
Scientific calculator gives students, teachers, scientists and engineers the power to find values for even the most complex equation set. You can build equation set, which can include a wide array of linear and nonlinear models for any application.
*Linear equations
*Polynomial and rational equations
*Nonlinear exponential, logarithmic and power equations
*Pre-defined mathematical and physical constants
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.
The data showed that treatment with SAR236553/REGN727 over 8 to 12 weeks significantly reduced mean low-density lipoprotein-cholesterol (LDL-C, or “bad” cholesterol) by 40% to 72% in patients with elevated LDL-C on stable dose of statins.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55299-sanofi-regeneron-pharmaceuticals-lipid-lowering-medications-pcsk9-antibody
As part of its charitable giving program, jcp cares, jcpenney is supporting The Breast Cancer Research Foundation, an organization committed to funding scientific research to achieve prevention and a cure for breast cancer in our lifetime. This October, in honor of breast cancer awareness month, jcpenney customers can round up their store purchases to the nearest whole dollar and donate the difference to The Breast Cancer Research Foundation.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54268-jcpenney-invites-customers-to-support-breast-cancer-research-foundation
To speed progress against cancer and other diseases, the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project today announced the largest-ever release of comprehensive human cancer genome data for free access by the global scientific community. The amount of information released more than doubles the volume of high-coverage, whole genome data currently available from all human genome sources combined. This information is valuable not just to cancer researchers, but also to scientists studying almost any disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52993-st-jude-childrens-research-hospital-comprehensive-human-cancer-genome-data
New findings from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project (PCGP) have helped identify the mechanism that makes the childhood eye tumor retinoblastoma so aggressive. The discovery explains why the tumor develops so rapidly while other cancers can take years or even decades to form.
The finding also led investigators to a new treatment target and possible therapy for the rare childhood tumor of the retina, the light-sensing tissue at the back of the eye. The study appears in the January 11 advance online edition of the scientific journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46767-st-jude-genome-project-treatment-childhood-eye-tumor-retinoblastoma
Millions of young people across the nation will become scientists for the day tomorrow, during the fifth annual 4-H National Youth Science Day (NYSD). This annual event seeks to spark an early youth interest in science education and future careers, and to reclaim the nation’s position of leadership in scientific exploration. As part of 4-H NYSD, youth will participate in the 4-H Eco-Bot Challenge: the 2012 National Science Experiment at hundreds of local events taking place in all 50 states. (See our online event map for time and location information).
To view Multimedia News Release, go to http://www.multivu.com/mnr/58326-4-h-national-youth-science-day-nysd-eco-bot-challenge
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, has announced the availability of an extensive set of advanced predictive sciences applications and services. These integrated capabilities enable drug discovery teams to investigate and evaluate hypotheses about the chemical or biological behavior of molecules of therapeutic interest in silico prior to costly experimentation. Accelrys predictive sciences leverages the open, scientifically aware Accelrys Enterprise Platform to deliver an advanced scientific decision support environment that reduces time and expense, improves quality, enhances collaboration and accelerates innovation in bringing new drugs to market.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62190-accelrys-offers-integrated-predictive-sciences-solutions-faster-innovation
Investment in basic research, convergence across disciplines and better engagement between academia and industry are key to the future of innovation, according to a panel of renowned thought leaders speaking at the celebration of the 2013 Dr. Paul Janssen Award for Biomedical Research.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63340-johnson-and-johnson-dr-paul-janssen-global-innovation-thermosensation
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, today announced that it has acquired Ireland-based QUMAS, a leading global provider of Cloud-based and on-premises enterprise compliance software supporting regulatory and quality operations in life sciences and other highly regulated industries. The QUMAS acquisition further extends Accelrys’ informatics portfolio with the addition of mission-critical, end-to-end document and process management compliance solutions. Proven quality management solutions supported by robust content and business process management capabilities provided by QUMAS advance Accelrys’ ability to help customers better manage the scientific innovation lifecycle by reducing regulatory risks, lowering quality costs, improving compliance effectiveness and increasing operational efficiency in bringing new products to market.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62188-accelrys-acquires-compliance-and-quality-management-leader-qumas
Leading scientists have released the latest results of the large scale trials related to nuts consumption and health, particularly in myocardial infarction, stroke and cardiovascular diseases. Recent scientific studies show the benefits of regular intake of nuts, not only associated with cardiovascular health but also with renal function, diabetes, cognitive function, atherosclerosis, metabolic syndrome, inflammatory biomarkers, etc. It is important to highlight that scientific evidence demonstrates that eating nuts is not associated with a higher risk of weight gain, and even reinforce their importance as sources of key nutrients.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62432-scientifically-proven-nuts-are-not-fattening
http://debbiewilliamsassociates.co.uk/ditch_the_dairy.htm Chrones disease and ulcerated colitis. My mother suffered for over 35 plus years with this and had a colostomy bag as well after a spell in hospital in an unrelated illness she was in a coma for 9 days and when she came home through dietary changes she stopped suffering. Debbie changed her diet getting all dairy products out from cheese to pizza to cream cakes and milk . This stopped the pain as you will see in the video her mothers response when given some custard in the hospital how the pain came on very suddenly. Debbie herself steers clear of dairy as it seems to cause her to feel blocked up and other unpleasant side effects. Many people are lactose intolerant without realizing it and suffer low level discomfort from irritable bowel to cramping pains not knowing that dairy products may be causing this.Creating a meal plan for a couple of weeks and then gradually adding in one dairy based food at a time will let you know whether its a problem for you or not. Debbie's mother was able to have the occasional cream cake once a week and her body could handle it but after 6 years of following eating foods that Debbie prepared she started buying lots of junk food and eating out more often with cream cakes everyday the downfall was dramatic and despite Debbie trying to stop her this time as she had a new baby to contend with Olive went downhill fast and was dead within 6 months.There is a saying we are digging our graves with out teeth, the link above takes you to a hypnosis product ditch the dairy if you feel you are addicted to dairy foods and need help to get them out to test if this will help you. Also check out www.notmilkman.com where there are tons and tons of scientific references linking dairy to all sorts of diseases. Also if you would like to have a free hypnosis recording my 'Stop worrying and create a wonderful life will help you. You can get it free from here:http://www.debbiewilliamsassociates.co.uk/. Back to the top:http://www.youtube.com/my_videos_edit?ns=1&video_id=0NU5jAiSWuA
